We are pleased to offer cell line identification through a DNA profiling method known as barcode analysis.
The 360 Diagnostics™ R&D team recently completed the validation of new PCR assays for infectious diseases that commonly affect zebrafish colonies.
Charles River now has the ability to monitor animal behavior in home cages for periods of up to 9 months.
Charles River has invested in a BD LSRFortessa™ X-20 flow cytometer to support preclinical development in immunobiology.
Our Safety Pharmacology investigators have recently completed a study on the effects of social housing on continuous myocardial contractility as part of standard preclinical cardiovascular evaluations.
Dr. David Hutto recently joined our team as the Chief Scientific Officer for the Safety Assessment division. Dr. Hutto will ensure the quality and alignment of the safety assessment sciences across all relevant units and sites within Charles River.
Repurposing known compounds or mechanisms may be a very effective way to improve the efficiency of pharmaceutical R&D. With emerging access to large pharmaceutical company compounds, there is a golden opportunity to investigate novel treatments.
Inspired by the Alzheimer's Association's nationwide fundraising event hosted annually on the summer solstice, Charles River’s Longest Day promoted Alzheimer’s disease education, brain health and physical activity at our sites globally.
Charles River has acquired Celsis International Ltd, a leading provider of rapid microbial detection systems for quality control testing in the biopharmaceutical and consumer products industries. The combination of Charles River and Celsis will drive significant value for our clients’ in-process and product release testing needs across a broad range of microbial detection applications.
ChanTest, a Charles River company, in collaboration with the FDA, is developing high-throughput assays to evaluate the pharmacology of tobacco product constituents and project their physiological impact.